Monteverde & Associates Scrutinizes Four Major Corporate Mergers

Shareholders of Arcosa, Crinetics Pharmaceuticals, Leggett & Platt, and LivePerson face critical voting deadlines this August and September. New York-based law firm Monteverde & Associates is currently investigating the fairness of these pending acquisitions, urging investors to evaluate whether the proposed deal terms adequately protect their financial interests.

Money Talk·August 3, 2026·reads: 495

Monteverde & Associates Scrutinizes Four Major Corporate Mergers

The investigation centers on four distinct transactions, each approaching final shareholder approval. For Arcosa (NYSE: ACA), investors are slated to receive $150.00 per share in cash ahead of a September 4, 2026, vote. Crinetics Pharmaceuticals (NASDAQ: CRNX) shareholders are expected to receive $85.00 per share in a sale to Vertex Pharmaceuticals, with a vote scheduled for August 28, 2026.

Additional scrutiny applies to the acquisition of Leggett & Platt (NYSE: LEG) by Somnigroup International, where shareholders are set to receive 0.1455 shares of common stock. Finally, LivePerson (NASDAQ: LPSN) faces investigation regarding its $43 million equity sale to SoundHound AI. Both the Leggett & Platt and LivePerson votes are set for August 20, 2026.

Attorney Juan Monteverde, whose firm is based in the Empire State Building, encourages stockholders to seek counsel regarding these transitions. The firm, recognized in the 2025 ISS Securities Class Action Services Report, maintains that shareholders should verify the litigation history of any firm they consult before proceeding with legal challenges.